Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | CA9 | Q16790 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | PPARG | P37231 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2372160 | 0.83 | MAPK1 (0.62) | MAPTMAPK1CA1CA2CA9 | |
| SCHEMBL12000927 | 0.83 | GAA (0.64) | MAPTMAPK1CA1CA2CA9 | |
| SCHEMBL5806238 | 0.83 | MAPK1 (0.67) | MAPTMAPK1CA1CA2CA9 | |
| SCHEMBL13949767 | 0.82 | POLB (0.68) | MAPTMAPK1CA1CA2CA9 | |
| SCHEMBL20750437 | 0.82 | POLB (0.64) | MAPTMAPK1CA1CA2CA9 | |
| SCHEMBL12132459 | 0.82 | ALDH1A1 (0.58) | MAPTMAPK1CA1CA2CA9 | |
| SCHEMBL5881832 | 0.81 | MAPK1 (0.60) | MAPTMAPK1CA1CA2CA9 | |
| SCHEMBL863061 | 0.80 | MAPK1 (0.68) | MAPTMAPK1CA1CA2CA9 | |
| SCHEMBL1507919 | 0.80 | SLC40A1 (0.76) | GAAPOLBALDH1A1KMT2AMEN1 | |
| SCHEMBL5881829 | 0.80 | MAPK1 (0.58) | MAPTMAPK1CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988448-B2 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| EP-3241554-B1 | QUINOLINE-8-SULFONAMIDE DERIVATIVES HAVING AN ANTICANCER ACTIVITY | AGIOS PHARMACEUTICALS INC (US) | 2020-01-29 | — | — | EP | disclosed |
| US-20190345109-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. | 2019-11-14 | — | — | US | disclosed |
| EP-2704720-B1 | PYRUVATE KINASE R ACTIVATORS FOR USE IN THERAPY | AGIOS PHARMACEUTICALS INC (US) | 2019-08-07 | — | — | EP | disclosed |
| US-9199959-B2 | HIV replication inhibitor | SHIONOGI & CO., LTD. (JP) | 2015-12-01 | — | — | US | disclosed |
| WO-2015081284-A1 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
| WO-2015081280-A1 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION | COFERON, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
| US-20140249306-A1 | HIV REPLICATION INHIBITOR | SHIONOGI & CO., LTD. (JP) | 2014-09-04 | — | — | US | disclosed |
| US-20140243321-A1 | BIOORTHOGONAL MONOMERS CAPABLE OF DIMERIZING AND TARGETING BROMODOMAINS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243286-A1 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20100197667-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100197667-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-7728144-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC (US) | 2010-06-01 | — | — | US | disclosed |
| US-7728144-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC (US) | 2010-06-01 | — | — | US | disclosed |
| US-20090069320-A1 | Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof | GRUENENTHAL GMBH (DE) | 2009-03-12 | — | — | US | disclosed |
| WO-2008116920-A2 | 17BETA-HYDROXYSTEROID-DEHYDROGENASE TYPE 1 INHIBITORS FOR THE TREATMENT OF HORMONE-DEPENDENT DISEASES | Universität des Saarlandes (DE) | 2008-10-02 | — | — | WO | disclosed |
| US-20080008681-A1 | MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-01-10 | — | — | US | disclosed |
| WO-2008002924-A2 | QUINOXALINYL MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-01-03 | — | — | WO | disclosed |
| US-7189720-B2 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2007-03-13 | — | — | US | disclosed |
| EP-0495594-A1 | Sulphonamide derivatives | ZENECA LIMITED (GB) | 1992-07-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197667-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM3, CHRM5 | MAPT 3983/4885MAPK1 3789/4885CA1 3720/4885 |
| US-20140243286-A1 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | BRDT, BRD4, BRD1 | MAPT 1845/4885MAPK1 1163/4885CA1 2152/4885 |
| US-10988448-B2 | Therapeutic compounds and compositions | PDK1, PDK2, PDK3 | MAPT 2867/4885MAPK1 1197/4885CA1 3941/4885 |
| US-20080008681-A1 | MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | PRSS1, SPINT2, TMPRSS4 | MAPT 4162/4885MAPK1 1331/4885CA1 1666/4885 |
| US-20140249306-A1 | HIV REPLICATION INHIBITOR | SSU72, RTF2, ZC3HAV1 | MAPT 3377/4885MAPK1 1653/4885CA1 4837/4885 |
| US-20190345109-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PDK2, PDK3 | MAPT 2867/4885MAPK1 1197/4885CA1 3941/4885 |
| US-20090069320-A1 | Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof | GRM1, GRIN1, GRM2 | MAPT 1623/4885MAPK1 1852/4885CA1 1637/4885 |
| US-20140243321-A1 | BIOORTHOGONAL MONOMERS CAPABLE OF DIMERIZING AND TARGETING BROMODOMAINS, AND METHODS OF USING SAME | BRDT, BRD4, BRD1 | MAPT 2022/4885MAPK1 1081/4885CA1 2321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.